Botox for Cervical Dystonia Following EMG Mapping - Full Text View

Sponsors and Collaborators:	University of California, San Francisco Allergan
Information provided by:	University of California, San Francisco
ClinicalTrials.gov Identifier:	NCT00773253

Purpose

The purpose of this study is to determine how to improve treatment of patients with cervical dystonia who have not been helped with standard Botox injections. This study is for patients with cervical dystonia who have not benefited from treatment with Botox using conventional "single lead electromyographic (EMG) techniques" for injection. The study aim is to see if these patients may have significantly more benefit if their Botox is injected into muscles that have been chosen with a multi-channel EMG mapping study of the neck prior to Botox injection.

Condition	Intervention	Phase
Cervical Dystonia	Drug: Botulinum toxin A	Phase IV

Genetics Home Reference related topics: early-onset primary dystonia familial paroxysmal nonkinesigenic dyskinesia

MedlinePlus related topics: Botox Dystonia

Drug Information available for: Clostridium botulinum toxin Botulinum toxin A

U.S. FDA Resources

Study Type:	Interventional
Study Design:	Treatment, Randomized, Open Label, Crossover Assignment, Efficacy Study
Official Title:	Pre-Injection, Multi-Channel EMG Mapping to Optimize Botulinum Toxin Type A Efficacy in Cervical Dystonia.

Further study details as provided by University of California, San Francisco:

Primary Outcome Measures:

Pre- and post-injection Toronto Western Spasmodic Torticollis Rating Scale(TWSTRS): Global Clinical Impression Scale (GCI); Visual Analog Scale(VAS) [ Time Frame: pre-injection, week 16, 20, 36, and 40 ] [ Designated as safety issue: No ]

Estimated Enrollment:	10
Study Start Date:	April 2008
Estimated Study Completion Date:	October 2010
Estimated Primary Completion Date:	April 2010 (Final data collection date for primary outcome measure)

Arms	Assigned Interventions
standard EMG-guided Botox injection: Active Comparator All patients will undergo injection using conventional single channel EMG-guided technique. This will be used as a baseline for multi-channel mapping-based injections. Patients will be randomized to undergo single-channel vs. multi-channel assessment upon study entry and will then cross over to the alternate arm.	Drug: Botulinum toxin A All patients will be treated with Botox using both single-channel and multi-channel EMG mapping.
Multi-channel EMG-guided Botox injection: Experimental Patients will receive multi-channel EMG-guided Botox injection before or after they have been treated with single-channel EMG-guided Botox, depending on which group they are assigned in the cross-over design.	Drug: Botulinum toxin A All patients will be treated with Botox using both single-channel and multi-channel EMG mapping.

Detailed Description:

The most common type of primary late-onset dystonia is cervical dystonia. Botulinum toxin A (BTX-A) injections are a safe and effective treatment for cervical dystonia in a majority of patients, however, a significant minority of patients (between 15 and 25%) have a suboptimal response to Botulinum toxin therapy. It is unclear why some patients do not respond maximally to neurotoxin therapy.

Studies using needle electromyographic "mapping" in the evaluation of cervical dystonia have revealed that clinical examination alone is insufficient for determining which muscles contribute to the dystonic movement. When compared to needle electromyography (EMG) "mapping studies", experienced movement disorders specialists correctly identify only 59% of active muscles and believe that 25% of muscles which upon EMG evaluation are found to be quiescent, are involved in the dystonia. The selection of incorrect muscles for injection of Botulinum toxin may explain why some patients have a sub-optimal response.

This study seeks to measure outcomes when the muscles involved in dystonia are identified using "mapping" via an 8-12 channel EMG. In the proposed study, the most involved/active dystonic muscles will be correctly identified through simultaneous 8-12 channel mapping resulting in a more informed injection strategy, which may improve response to Botulinum toxin A treatment as compared to single lead EMG based injections. This study changes routine clinical care only by adding the step of studying the muscles of the neck with simultaneous EMG mapping to allow a more objective injection strategy.

Eligibility

Ages Eligible for Study:	18 Years to 75 Years
Genders Eligible for Study:	Both
Accepts Healthy Volunteers:	No

Criteria

Inclusion criteria:

Male or female subjects, 18 to 75 years of age.
Ability to follow study instructions and complete all required visits.
Subject meets diagnostic criteria for idiopathic primary cervical dystonia.
Subject has at least moderate severity Cervical Dystonia, with a baseline rating of at least 30 on the total TWSTRS and at least 15 on the TWSTRS motor severity subsection.
Patients have had a suboptimal response to 2 previous Botulinum toxin injections at an outside facility.
Patients will not have received Botulinum toxin within 16 weeks of the start of the study.
In order to not confound the clinical response to BTX-A injections, all patients enrolled must have been on a stable medication regimen for 30 days. If they are not on medication at the initiation of the study, they will not be started on medication. Patients must be on the same medication regimen through the entire study including assessment of both single lead EMG based injections and "mapping" based injections. Medications cannot be stopped during the study to avoid confounding the clinical response to BTX-A.

Exclusion Criteria:

Known allergy or sensitivity to any of the components in BTX-A.
Uncontrolled clinically significant medical condition other than the condition under evaluation
Females with a positive pregnancy test, or who are breast-feeding, planning a pregnancy during the study, who think that they may be pregnant at the start of the study or females of childbearing potential who are unable or unwilling to use a reliable form of contraception during the study.
Participation in another medication or device study or within 3 months of enrollment in this study.
Patients know to have a positive frontalis test or have previously tested positive for the presence of BTX-A antibodies will be excluded.
Any known evidence of cervical contractures or significant spinal deformity.

Contacts and Locations

Please refer to this study by its ClinicalTrials.gov identifier: NCT00773253

Contacts

Contact: Jamie Grace, B.S.	415-353-8328	jamie.grace@ucsf.edu
Contact: Graham A. Glass, M.D.	415-221-4810 ext 2657	graham.glass@ucsf.edu

Locations

United States, California
University of California, San Francisco	Recruiting
San Francisco, California, United States, 94143
Contact: Jamie Grace, B.S. 415-353-8328 jamie.grace@ucsf.edu
Contact: Graham A. Glass, M.D. 415-221-4810 ext 2657 graham.glass@ucsf.edu
Principal Investigator: Graham A. Glass, M.D.
San Francisco Veterans Administration Medical Center	Recruiting
San Francisco, California, United States, 94121
Contact: Susan Heath, M.S.N. 415-221-4810 ext 2505 Susan.Heath@va.gov

Sponsors and Collaborators

University of California, San Francisco

Allergan

More Information

Responsible Party:	University of California, San Francisco ( Graham A. Glass, M.D. )
Study ID Numbers:	Allergan cervical dystonia
Study First Received:	October 14, 2008
Last Updated:	October 22, 2008
ClinicalTrials.gov Identifier:	NCT00773253
Health Authority:	United States: Institutional Review Board

Keywords provided by University of California, San Francisco:

dystonia
cervical dystonia
Botox
idiopathic primary cervical dystonia

Study placed in the following topic categories:

Dystonic Disorders
Signs and Symptoms
Torticollis
Botulinum Toxins
Movement Disorders

Central Nervous System Diseases
Neurologic Manifestations
Dystonia
Botulinum Toxin Type A
Dyskinesias

Additional relevant MeSH terms:

Anti-Dyskinesia Agents
Therapeutic Uses
Nervous System Diseases
Central Nervous System Agents
Pharmacologic Actions

ClinicalTrials.gov processed this record on January 16, 2009